SAN JOSE, Calif. -- (BUSINESS WIRE) -- DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced it has entered into an exclusive distribution agreement with Biomet, Inc. for its StabiliT® Vertebral Augmentation System in Spain and Portugal. The term of the distribution agreement will be for three years.
The StabiliT System harnesses the power of RadioFrequency Targeted Vertebral Augmentation (RF-TVA™) to relieve pain and repair vertebral compression fractures (VCFs) resulting from instability due to osteoporosis or cancer.
“Physicians continue to demand an option that is not only minimally invasive, but that also provides control, safety and predictable results. StabiliT fills that need and offers a generational advance in the treatment of spine fractures,” said DFINE Chief Executive Officer Kevin Mosher. “The agreement with Biomet will allow us to build a solid commercial position within Spain and Portugal as part of our worldwide expansion strategy. We are excited about our new relationship with Biomet and look forward to building a strong business on the Iberian Peninsula.”
About DFINE, Inc.
DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from vertebral pathologies through innovative, minimally invasive, targeted therapies. The company’s devices are built on an extensible radiofrequency (RF) platform that currently covers two procedural applications: 1. The treatment of vertebral compression fractures (VCFs) with the StabiliT® Vertebral Augmentation System, and 2. The palliative treatment of metastatic vertebral body lesions with the STAR™ Tumor Ablation System. Both systems represent generational advancements in the minimally invasive treatment of vertebral pathologies. DFINE is based in San Jose, Calif. and is a privately held company. Stay connected with DFINE via Facebook or Twitter (@DFINEinc) or call 1.866.963.3463.
Headquartered in Warsaw, Indiana, Biomet, Inc. and its subsidiaries design, manufacture, and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Biomet and its subsidiaries distribute medical device products in approximately 90 countries and have more than 7,000 representatives worldwide. The company has annual sales of more than $2.5 billion.